| Authors: |
Grinda T; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Gustave Roussy, Medical Oncology Department, Villejuif, France., Heiling HM; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Tayob N; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Smith KL; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Davis R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cotter C; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., DeMeo MK; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Santa-Maria CA; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Van Poznak C; University of Michigan, Ann Arbor, MI, USA., Moy B; Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA., Brufsky AM; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Melisko ME; University of California at San Francisco, San Francisco, CA, USA., O'Sullivan CC; Mayo Clinic, Rochester, MN, USA., Isaacs C; MedStar/Georgetown University, Washington, DC, USA., Rauf Y; University of North Carolina, Chapel Hill, NC, USA., Nangia JR; Baylor College of Medicine, Houston, TX, USA., Burns RT; The Emmes Corporation, Rockville, MD, USA., Savoie J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Emmes Corporation, Rockville, MD, USA., Wolff AC; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Winer EP; Yale Cancer Center, New Haven, CT, USA., Mayer EL; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Rimawi MF; Baylor College of Medicine, Houston, TX, USA., Ruddy KJ; Mayo Clinic, Rochester, MN, USA., Rocque G; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA., Krop IE; Yale Cancer Center, New Haven, CT, USA., Lin NU; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Freedman RA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: rachel_freedman@dfci.harvard.edu. |
